<DOC>
	<DOCNO>NCT01377974</DOCNO>
	<brief_summary>The purpose study determine whether miltefosine effective treatment mucosal leishmaniasis compare meglumine antimoniate , standard treatment .</brief_summary>
	<brief_title>Clinical Trial Miltefosine Treat Mucosal Leishmaniasis</brief_title>
	<detailed_description>Mucosal leishmaniasis rare form disease , affect 6 % patient cutaneous leishmaniasis New World . It cause deformity may lethal treat . It part neglect tropical disease past sixty year progress regard treatment option improvement quality life patient . Also , little interest pharmaceutical industry government authority develop new research . The standard treatment , meglumine antimoniate , toxic , invasive , require trained personnel many adverse effect restriction . On hand , miltefosine first oral drug demonstrate efficacy mucocutaneous leishmaniasis . Few clinical trial perform Central South American country , far , one involve mucosal leishmaniasis patient , compare miltefosine amphotericin B . None study compare efficacy standard treatment do .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Mucocutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Clinical diagnosis mucosal leishmaniasis Not previously treat , last treatment must occur 6 month enrollment study Use contraceptive method , female child bear age Sign agreement consent form Previous leishmanicidal treatment past 6 month enrollment study Electrocardiogram abnormalities pretreatment exams Previous kidney , liver and/or heart diseases Diabetes Mellitus Hypersensitivity miltefosine meglumine antimoniate Pregnant woman breastfeed mother Hiv patient</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Mucocutaneous Leishmaniasis</keyword>
	<keyword>Therapeutics</keyword>
	<keyword>meglumine antimoniate</keyword>
	<keyword>miltefosine</keyword>
</DOC>